Importantly, we were able to confirm the upregulation of CD300A in BRCA, GBM, head and neck squamous cell carcinoma (HNSC), KIRC, PAAD, uterine corpus endometrial carcinoma (UCEC), and the downregulation of CD300A in liver hepatocellular carcinoma (LIHC) (except for LUAD and OV, which showed an opposite pattern of protein expression) (Figure 1C and Figure S1). Here, CD300A is linked to glioblastoma.